Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
the same patient at 1.0 g/kg sits at 82 g/day
It does so by the following ways: eating prompts insulin secretion, glucagon levels are lowered, gastric emptying is slowed down, and satiety is encouraged
These results are consistent with SURPASS2, a 40week, openlabel, phase 3 trial in a cohort of patients with metformintreated T2D in which onceweekly tirzepatide (5, 10, or 15 mg) was noninferior and superior to semaglutide 1 mg for HbA1c reduction and produced substantially greater, dosedependent weight loss
Pricing negotiations focus on value-based models due to its efficacy
US$ 21.44
US$ 23.40
US$ 22.42
